Making breakthrough medicines is hard.
Developing new medicines is one of the hardest and most important product development endeavours in any industry. When it works, it is a miracle of science and technology, delivering medicines that improve health, alleviate suffering, and save lives.
Our vision is to build a company that can repeatedly beat the odds to deliver these medicines.
Motivated by work that really matters.
Creating medicines is the most important work we can do. When tenacious people share a vision and work together, they can truly have a positive impact. That’s why we hire for character and intelligence, not just for CVs or experience. We look for people with drive and energy. People we trust.
People who need to know their days are being well spent. That their work really matters.
From a technology company to a clinical biotech.
Technologies for faster and better antibody discovery.
Searching natural immunes responses to find better antibody medicines. AbCellera grew out of an academic lab where six scientists had the idea that microfluidics and single-cell analysis could be the basis for increasing the productivity of antibody drug development. Instead of focusing on developing one drug, our founders and early team members made long-term investments in technologies that would make it possible to create many medicines.
Engineered through partnerships.
Working with industry innovators on 100+ discovery programs. Our platform was built over a decade of partnerships with biotech and pharmaceutical companies working to solve some of the most challenging problems in antibody discovery. Through these partnerships, we built world-leading capabilities that integrate proprietary technologies, know-how, infrastructure, and teams. We have completed over 100 therapeutic antibody discovery programs across multiple targets, indications, and modalities. In addition to being a driver for technology development, our partnership business has built a portfolio of passive royalty stakes in our partners’ drug programs.
To create a pipeline of innovative antibody medicines.
One platform, from target to clinic. Today, our platform includes fully integrated capabilities to create first-in-class and best-in-class antibody medicines, from discovery to clinical manufacturing. In 2023 we made the decision to shift our focus from partnerships to advancing our own pipeline of internal and co-development programs. We are using our technological advantage to develop programs across multiple indications including endocrine and metabolic conditions, oncology, and inflammation & autoimmunity.
Our team.
Jessica Patterson
Head of Target Assessment
When I saw a Canadian company tackling such globally impactful problems, I immediately wanted to join the team. Everyone I work with is engaged, interested, and passionate about the work we are doing!
Grace Leung
Associate Scientific Director
I wanted to keep doing work that could directly impact patient health. AbCellera allows me to do that, all while working with an incredibly collaborative team who do what it takes to get the job done together.
Róisín McComb
Laboratory Operations Manager
AbCellera provides me with opportunities to grow both scientifically and personally. I love working alongside such passionate, amazing team members contributing to cutting-edge science.
Mark Lowson
Lead, Screening Software
I like helping motivated teams design software to solve challenging problems. I’m fortunate to work with a talented team who are innovating throughout the company and leveraging new technologies to achieve great things together.
People connected in purpose.
We hire for character and intelligence. People we trust.
One platform, from target to clinic.
